Onyx Pharms Amgen Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ONYX PHARMS AMGEN, and what generic alternatives to ONYX PHARMS AMGEN drugs are available?
ONYX PHARMS AMGEN has one approved drug.
There are eleven US patents protecting ONYX PHARMS AMGEN drugs.
There are one hundred and ninety-one patent family members on ONYX PHARMS AMGEN drugs in forty-two countries and eighteen supplementary protection certificates in sixteen countries.
Summary for Onyx Pharms Amgen
International Patents: | 191 |
US Patents: | 11 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drugs and US Patents for Onyx Pharms Amgen
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | AP | RX | Yes | Yes | 8,207,126 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | 8,207,127 | ⤷ Sign Up | ⤷ Sign Up | ||||
Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | 8,207,125 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | 7,737,112 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | 8,207,126 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ONYX PHARMS AMGEN drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | For Injection | 10 mg/vial | ➤ Subscribe | 2018-11-28 |
➤ Subscribe | For Injection | 60 mg/vial | ➤ Subscribe | 2016-07-20 |
International Patents for Onyx Pharms Amgen Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Eurasian Patent Organization | 024364 | ⤷ Sign Up |
European Patent Office | 3101026 | ⤷ Sign Up |
Hong Kong | 1152047 | ⤷ Sign Up |
European Patent Office | 2564834 | ⤷ Sign Up |
Austria | E496062 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Onyx Pharms Amgen Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1781688 | 93015 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CARFILZOMIB EVENTUELLEMENT SOUS FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; FIRST REGISTRATION: 20151123 |
1781688 | CR 2016 00014 | Denmark | ⤷ Sign Up | PRODUCT NAME: CARFILZOMIB OG FARMACEUTISK ACCEPTABLE SALTE HERAF; REG. NO/DATE: EU/1/15/1060 20151123 |
1781688 | SPC/GB16/022 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: CARFILZOMIB OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/15/1060 20151123 |
1781688 | 1690013-6 | Sweden | ⤷ Sign Up | PRODUCT NAME: CARFILZOMIB OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/15/1060 20151123 |
1781688 | 16C0017 | France | ⤷ Sign Up | PRODUCT NAME: CARFILZOMIB; REGISTRATION NO/DATE: EU/1/15/1060 20151123 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.